Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603925 · ClinicalTrials.gov registry record
Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 37
- Enrollment target
NCT03603925: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT03603925 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603925 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
Standardized Uptake Values (SUVs), normalized activity concentration, measured using PET/MR have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative Imaging Biomarkers Alliance (RSNA/QIBA) specifications and disqualifies PET/MR from multicenter or cooperative group clinical trials. High inaccuracy is primarily due to poor attenuation correction (AC) owing to lack of computed tomography (CT) data. This study will develop acquisition and analyses methods to synthesize CT images from MR data that can be used to achieve SUVs that are within 5% of those obtained using PET/CT (reference standard), thus meeting accuracy requirements needed to qualify for multicenter trials. The overall goal of this research project is to validate clinically practical methods for producing MR-based attenuation correction information which is needed to produce quantitatively accurate PET images from a PET/MR scanner. Existing commercial PET/MR systems use methods that are inaccurate.
Primary Outcome
Demonstrate quantitative agreement between measured CT and CT synthesized from MR data
Interventions
- DIAGNOSTIC_TEST Positron Emission Test / Magnetic Resonance (PET/MR)
- DIAGNOSTIC_TEST Positron Emission Test / Computed Tomography (PET/CT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2021-04-07 |
What the finished NCT03603925 record still lists
NCT03603925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Positron Emission Test / Magnetic Resonance (PET/MR) is the first listed.
NCT03603925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03603925 about?
NCT03603925 is a clinical study titled "Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification". Standardized Uptake Values (SUVs), normalized activity concentration, measured using PET/MR have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative Imaging Biomarkers Alliance (R...
What is the current status of trial NCT03603925?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2019-06-17. Estimated completion is 2021-04-07.
What interventions are being tested in trial NCT03603925?
The interventions under investigation include: Positron Emission Test / Magnetic Resonance (PET/MR) (DIAGNOSTIC_TEST), Positron Emission Test / Computed Tomography (PET/CT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03603925?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI